A Bottom Has Been Established; Possible Retest?
In today’s report we outline our belief that the combination of extreme oversold conditions and several key sectors/industries holding above major...
365 Views
SELL Ascletis Pharma: Why the COVID-19 Update Does Not Make Sense
We have previously discussed the short idea of Ascletis Pharma. After a few days of retreat, the stock reacted positively today to the news related...
334 Views
U.S. Equity Strategy: Upgrading Health Care to Overweight
Ongoing bullish developments continue to support our belief that we are in the early stages of a broad-based advance following a nearly 2-year...
376 Views
Immunotech Biopharm (永泰生物) IPO: Challenges for Cellular Immunotherapies
Immunotech Biopharma, a leading cellular immunotherapy company in China, aims to raise USD 100 to 200 million via a Hong Kong listing. In this...
792 Views
Japan CAR-T Therapy Landscape
Japan CAR-T therapy - Competitive landscapeJapan pharma catching-up with global players… but a large gap remains Novartis AG (NOVN SE)’ Kymriah...
1.1k Views